title: Novel inflammatory marker in dialysis patients: YKL-40.
abstract: YKL-40 has been introduced as a marker of inflammation in different clinical situations. The association between YKL-40 and inflammation in chronic renal failure patients has not been researched currently. The objectives of this study were to establish serum YKL-40 concentrations in dialysis patients with chronic renal failure compared to healthy subjects and to explore its relationships with a proinflammatory cytokine, interleukine-6 (IL-6) and an acute phase mediator, high sensitivity C-reactive protein (hs-CRP). The study population included hemodialysis patients (N = 43; mean age of 40.9 ± 14.5), peritoneal dialysis patients (N = 38; mean age of 45.8 ± 13.7) and healthy subjects (N = 37; mean age of 45.5 ± 10.6). Serum concentrations of YKL-40, IL-6, hs-CRP and routine laboratory measures were evaluated. Compared to the healthy subjects, hemodialysis and peritoneal dialysis patients had higher concentrations of YKL-40, IL-6, hs-CRP, as well as lower concentrations of hemoglobin, serum albumin and high density lipoprotein-cholesterol (P < 0.001). YKL-40 concentrations were positively correlated with serum creatinine (P < 0.001, r = 0.495), IL-6 (P < 0.001, r = 0.306), hs-CRP (P = 0.001, r = 0.306) levels and inversely correlated with hemoglobin (P = 0.002, r = -0.285), serum albumin (P < 0.001, r = -0.355) and high density lipoprotein-cholesterol (P = 0.001, r = -0.306). In multivariate regression analysis YKL-40 was associated with creatinine, serum albumin and hs-CRP concentrations after adjustments with covariates. Dialysis patients with chronic renal failure have elevated serum YKL-40 concentrations. Associations with standard inflammatory parameters suggest that YKL-40 might be a novel inflammatory marker in this population.
authors.affiliation: Department of Nephrology, Faculty of Medicine, Gazi University, Ankara, Turkey.
authors.forename: Gülay Ulusal
authors.initials: GU
authors.lastname: Okyay
authors.forename: Ramazan Erdem
authors.initials: RE
authors.lastname: Er
authors.forename: Merve Yasemin
authors.initials: MY
authors.lastname: Tekbudak
authors.forename: Özge
authors.initials: Ö
authors.lastname: Paşaoğlu
authors.forename: Salih
authors.initials: S
authors.lastname: Inal
authors.forename: Kürşad
authors.initials: K
authors.lastname: Öneç
authors.forename: Hatice
authors.initials: H
authors.lastname: Paşaoğlu
authors.forename: Kadriye
authors.initials: K
authors.lastname: Altok
authors.forename: Ülver
authors.initials: Ü
authors.lastname: Derici
authors.forename: Yasemin
authors.initials: Y
authors.lastname: Erten
mesh_terms: D054392:Adipokines / Q000097:blood*; D000328:Adult; D002097:C-Reactive Protein / Q000378:metabolism; D016022:Case-Control Studies; D000071451:Chitinase-3-Like Protein 1; D008076:Cholesterol, HDL / Q000097:blood; D003404:Creatinine / Q000097:blood; D003430:Cross-Sectional Studies; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000473:pathology; D015850:Interleukin-6 / Q000097:blood; D007676:Kidney Failure, Chronic / Q000628:therapy*; D037102:Lectins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010530:Peritoneal Dialysis; D012044:Regression Analysis; D006435:Renal Dialysis; D012709:Serum Albumin / Q000378:metabolism
chemical_list: D054392:Adipokines; C084533:CHI3L1 protein, human; D000071451:Chitinase-3-Like Protein 1; D008076:Cholesterol, HDL; D006454:Hemoglobins; D015850:Interleukin-6; D037102:Lectins; D012709:Serum Albumin; D002097:C-Reactive Protein; D003404:Creatinine